Clinical Trials Logo

Radiotherapy clinical trials

View clinical trials related to Radiotherapy.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06353061 Not yet recruiting - Cervical Cancer Clinical Trials

Chemoradiotherapy With or Without Metformin in Locally Advanced Cervical Cancer

Start date: April 15, 2024
Phase: Phase 2
Study type: Interventional

This is a prospective, single-center, phase II, randomized, window-of-opportunity trial initiated by researchers. The research hypothesis is that metformin can improve the level of hypoxia in locally advanced cervical cancer and further improve progression-free survival. The study aims to compare the improvement of tumor hypoxia with synchronous chemoradiotherapy with or without metformin, using CA-IX PET/CT and radiation positioning spectral CT to evaluate tumor hypoxia, screening hypoxic patients for inclusion in the study, and comparing the effects of synchronous chemoradiotherapy with or without metformin on the degree of hypoxia and progression-free survival in the two groups of patients.

NCT ID: NCT06330142 Not yet recruiting - Radiotherapy Clinical Trials

Hippotherapy Teenager-pediatric Radiotherapy

T-QAP
Start date: April 1, 2024
Phase: N/A
Study type: Interventional

This study proposes a horse-assisted therapy (HAT) approach to accompany children and young adults undergoing irradiation in the ICANS Radiotherapy Department. The aim of this new approach is to improve quality of life and reduce anxiety in children and adolescents treated with radiotherapy. The impact of equine-assisted therapy on quality of life and anxiety disorders will be described prospectively between the start and end of irradiation in children and parents who agree to inclusion.

NCT ID: NCT06262321 Not yet recruiting - Radiotherapy Clinical Trials

Thoracic Radiotherapy for Patients With Metastatic (Stage IV) Non-Small Cell Lung Cancer at High Risk of Symptomatic Progression Within the Thorax

DRO2301
Start date: June 1, 2024
Phase: Phase 2
Study type: Interventional

Patients with metastatic non small cell lung cancer with high risk location or size are treated with prophylactic radiation therapy in conjunction with standard of care systemic therapy.

NCT ID: NCT06249321 Not yet recruiting - Pancreatic Cancer Clinical Trials

mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer Refractory to Chemotherapy

PTCA199-10
Start date: April 1, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy of mFOLFIRINOX plus radiotherapy to Patients with CA19-9-normal Advanced Pancreatic Cancer refractory to chemotherapy.

NCT ID: NCT06197126 Not yet recruiting - Cervical Cancer Clinical Trials

MRI-based Signatures for Survival Prediction in Cervical Cancer With Radiotherapy

Start date: January 1, 2024
Phase:
Study type: Observational

This study aims to validate the value of tumor involvement features based on MRI in cervical cancer, facilitate the development of a more appropriate model for risk stratification, and help patients with varying risk profiles make appropriate decisions in treatment selection and follow-up plans.

NCT ID: NCT06168292 Not yet recruiting - Radiotherapy Clinical Trials

Intraductal Radiofrequency Thermoablation and Radiotherapy Combined Treatment for Extrahepatic Cholangiocarcinoma

Start date: December 10, 2023
Phase: N/A
Study type: Interventional

[Study objectives] To evaluate the efficacy and safety of the combined treatment of radiotherapy and endoscopic intraductal radiofrequency ablation in patients with locoregional extrahepatic cholangiocarcinoma.

NCT ID: NCT06101966 Not yet recruiting - Cervical Cancer Clinical Trials

A Predictive Model for Early Metastasis in Cervical Cancer Patients After Radiotherapy

Start date: December 1, 2023
Phase:
Study type: Observational

This study aims to help to screen out appropriate cases for consolidation therapy and more intensive follow up.

NCT ID: NCT06088056 Not yet recruiting - Breast Cancer Clinical Trials

A Phase II Study of T-DXd Plus SRT in HER2-positive Breast Cancer Brain Metastases

Start date: November 2023
Phase: Phase 2
Study type: Interventional

This research study will evaluate the efficacy and safety of stereotactic radiotherapy (SRT) combined with Trastuzumab-Deruxtecan (T-DXd; DS-8201a) in HER2-positive Breast Cancer Patients with newly diagnosed or progressing Brain Metastases.

NCT ID: NCT05909137 Not yet recruiting - NSCLC Clinical Trials

Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer

Start date: September 2024
Phase:
Study type: Observational

Simultaneous radiotherapy followed by adjuvant immunotherapy is the standard treatment modality of unresectable stage III NSCLC. Our preliminary study confirmed that the treatment of CTV-omitted IMRT regimen did not compromise the PFS or OS and significantly reduced the incidence of severe radiation pneumonia and radiation esophagitis. The purpose of this study was to observe the role of radiotherapy modalities that omit CTV in the context of immunotherapy for NSCLC.

NCT ID: NCT05874778 Not yet recruiting - Radiotherapy Clinical Trials

A Multicenter, Phase 2 Study Evaluating the Value of Radiotherapy in Advanced Diffuse Large B-cell Lymphoma Patients With Extranodal Involvement and Large Tumors Undergoing Immunochemotherapy for PET-CT Assessment of Complete Remission

Start date: May 15, 2023
Phase: Phase 2
Study type: Interventional

This study is a prospective, single center, phase II clinical study involving 108 patients with primary and late stage Diffuse Large B-cell Lymphoma complicated by large masses and extranodal involvement. The study aims to evaluate the efficacy of radiotherapy targeting large masses and extranodal involvement in treatment-naïve advanced DLBCL patients with large mass lesions and/or extranodal involvement after they had initially been treated with standard immunochemotherapy and received complete remission as assessed by PET-CT. After completing the standard immunochemotherapy, subjects will be randomly divided into the radiotherapy group or the non-radiotherapy group, and the curative effects will be evaluated every three months after the end of the treatment or after their leaving the group, so as to obtain the relevant data and data of the 2-year Progression Free Survival, survival of the subjects and Treatment-related side effects.